Current status of transarterial radioembolization

Table 3 Summary of studies comparing different treatments to ⁹⁰Y-transarterial radioembolization in hepatocellular carcinoma

Ref.	Patients (n)	Particle type	Stage	Design	Response (%)					Median survival (mo)
					CR	PR	SD	AR	PD
D'Avola et al[32]	35	Resin	CHILD A/B	Retrospective	NA	NA	NA	NA	NA	16
	43	Control			NA	NA	NA	NA	NA	8
Lewandowski et al[43]	43	Glass	UNOS T3	Retrospective	47	39	14	100	0	18.7
	43	TACE			17	54	26	97	3	35.7
Kooby et al[76]	27	Resin	Okuda I-III	Retrospective	0	11	56	87	33	6
	44	TACE			0	4	60	64	36	6
Salem et al[41]	123	Glass	BCLC A-D	Retrospective	NA	NA	NA	72	NA	20.5
	122	TACE			NA	NA	NA	69	NA	17.4
Lance et al[77]	38	Glass	CHILD A/B	Retrospective	NA	NA	NA	NA	NA	8
	35	TACE			NA	NA	NA	NA	NA	10.3
Moreno-Luna et al[26]	55	Glass	CHILD A/B	Retrospective	12	39	39	91	9	15
	61	TACE			4	47	34	85	15	14.4
Gramenzi et al[47]	63	Resin	BCLC B/C	Retrospective	14	54	14	72	28	13.2
	74	Sorafenib			0	10	42	52	48	14.4

CR: Complete response; PR: Partial response; SD: Stable disease; AR: Any response; PD: Progressive disease; NA: Not available; TACE: Transarterial chemoembolization; BCLC: Barcelona Clinic Liver Cancer; UNOS: United Network for Organ Sharing.